Skip to main content Accessibility help
×
Hostname: page-component-76fb5796d-22dnz Total loading time: 0 Render date: 2024-04-26T03:29:45.015Z Has data issue: false hasContentIssue false

102 - Ondansetron

Published online by Cambridge University Press:  06 October 2020

Stephen D. Silberstein
Affiliation:
Thomas Jefferson University, Philadelphia
Michael J. Marmura
Affiliation:
Thomas Jefferson University, Philadelphia
Hsiangkuo Yuan
Affiliation:
Thomas Jefferson University, Philadelphia
Stephen M. Stahl
Affiliation:
University of California, San Diego
Get access

Summary

THERAPEUTICS

Brands

• Zofran, Zuplenz

Generic?

• Yes

Class

• Antiemetic

Commonly Prescribed for

(FDA approved in bold)

Prevention of nausea and vomiting (chemotherapy, radiotherapy, postoperative)

• Nausea and vomiting (pregnancy)

• Pruritus (opioid related)

• Acute gastroenteritis vomiting (children)

How the Drug Works

• Selective blocking agent of 5-HT3 receptors on both peripheral vagal nerve terminal and central chemoreceptor trigger zone (area postrema)

How Long Until It Works

• Usually works in less than 30 minutes

If It Works

• Use at lowest effective dose

If It Doesn't Work

• Increase dose, or discontinue and change to another agent

Best Augmenting Combos for Partial Response or Treatment-Resistance

• May try adding D2 antagonist, NK1 antagonist, antihistamine, benzodiazepine, or corticosteroid

Tests

• None required

ADVERSE EFFECTS (AEs)

How the Drug Causes AEs

• Blocking of 5-HT3 receptors

Notable AEs

• Headache, flushing, arrhythmia, urticaria, constipation, fever

• Transient blurred vision, elevated hepatic function tests

Life-Threatening or Dangerous AEs

• Hypersensitivity

• QTc prolongation

Weight Gain

• Unusual

Sedation

• Unusual

What to Do About AEs

• Reduce dose or discontinuation

Best Augmenting Agents to Reduce AEs

• Symptomatic management

DOSING AND USE

Usual Dosage Range

• 8–32mg

Dosage Forms

• Tablets: 4, 8, 16, 24mg

• Orally disintegrating tablet: 4, 8mg

• Film: 4, 8mg

• Injection: 2mg/mL, 4mg/5mL, 32mg/50mL

How to Dose

• For chemotherapy-induced nausea/ vomiting: 8–32mg IV or orally 15–30 minutes before chemotherapy

• Before anesthesia induction: 4mg IV undiluted over 2–5 minutes

Dosing Tips

• Should be administered 30 minutes before emetogenic cancer chemotherapy; 1–2 hours before radiotherapy; or 1 hour before induction of anesthesia

Overdose

• Sudden blindness of 2–3 minutes, hypotension, or vasovagal episode has been reported

Long-Term Use

• No long-term side effect

Habit Forming

• No

How to Stop

• No need to taper

Pharmacokinetics

• Metabolized predominantly by CYP3A4. Half-life 3–6 hours

Type
Chapter
Information
Essential Neuropharmacology
The Prescriber's Guide
, pp. 375 - 377
Publisher: Cambridge University Press
Print publication year: 2015

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

  • Ondansetron
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.103
Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

  • Ondansetron
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.103
Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

  • Ondansetron
  • Stephen D. Silberstein, Thomas Jefferson University, Philadelphia, Michael J. Marmura, Thomas Jefferson University, Philadelphia, Hsiangkuo Yuan, Thomas Jefferson University, Philadelphia
  • Edited in consultation with Stephen M. Stahl, University of California, San Diego
  • Book: Essential Neuropharmacology
  • Online publication: 06 October 2020
  • Chapter DOI: https://doi.org/10.1017/9781316161753.103
Available formats
×